United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says

MT Newswires Live

Feb 27

United Therapeutics' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.

The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.

The "surprise announcement" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.

SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.

RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.

Price: 498.49, Change: -36.62, Percent Change: -6.84

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614247500"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614247500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614247500?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 01:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614247500","market":"hk","top_or_hot":-1,"title":"United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says","media":"MT Newswires Live","content":"<html><body><p> United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.</p><p>The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.</p><p>The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.</p><p>SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.</p><p>RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.</p><p>Price: 498.49, Change: -36.62, Percent Change: -6.84</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-02-27 01:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.</p><p>The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.</p><p>The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.</p><p>SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.</p><p>RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.</p><p>Price: 498.49, Change: -36.62, Percent Change: -6.84</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1699723380.USD","symbol_name":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614247500","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614247500","pubTimestamp":1772125988,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"United Therapeutics'  development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.RBC raised its price target on United Therapeutics to $643 from ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4139":"生物科技","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","BK4532":"文艺复兴科技持仓","UTHR":"美国联合医疗"},"translate_title":"加拿大皇家银行表示，United Therapeutics的Tyvaso软雾吸入器可能会提高市场份额","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"United Therapeutics' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.Price: 498.49, Change: -36.62, Percent Change: -6.84","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}